| Literature DB >> 24466378 |
Ludger Klewes1, Rhea Vallente1, Eric Dupas1, Carolin Brand2, Dietrich Grün3, Amanda Guffei1, Chirawadee Sathitruangsak4, Julius A Awe1, Alexandra Kuzyk1, Daniel Lichtensztejn1, Pille Tammur5, Tiiu Ilus5, Anu Tamm5, Mari Punab6, Morel Rubinger7, Adebayo Olujohungbe7, Sabine Mai8.
Abstract
Multiple myeloma (MM) is preceded by monoclonal gammopathy of undetermined significance (MGUS). Up to date, it is difficult to predict an individual's time to disease progression and the treatment response. To examine whether the nuclear telomeric architecture will unravel some of these questions, we carried out. Three-dimensional (3D) telomere analysis on samples from patients diagnosed with MGUS and MM, as well as from patients who went into relapse. Telomere signal intensity, number of telomere aggregates, nuclear volume, and the overall nuclear telomere distribution (a/c ratio) were analyzed. The telomeric profiles allowed for the differentiation of the disease stages. The telomeric profiles of myeloma cells obtained from blood and bone marrow aspirates were identical. Based on this study, we discuss the use of 3D telomere profiling as a potential future tool for risk stratification and personalized treatment decisions.Entities:
Year: 2013 PMID: 24466378 PMCID: PMC3890710 DOI: 10.1593/tlo.13613
Source DB: PubMed Journal: Transl Oncol ISSN: 1936-5233 Impact factor: 4.243